SCHEMBL25548883

SCHEMBL25548883

CC(C)(C)C[C@H](NC(=O)c1ccc2c(F)cccc2c1OCc1ccc(C(F)(F)F)cc1)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 2/20 0.47
KIFC1 Q9BW19 1/20 0.43
MCHR1 Q99705 2/20 0.43
MME P08473 1/20 0.41
ACE P12821 1/20 0.41
CPA1 P15085 1/20 0.41
ACE2 Q9BYF1 1/20 0.41
GPR132 Q9UNW8 1/20 0.40
MRGPRX4 Q96LA9 3/20 0.39
TACR1 P25103 1/20 0.39
SENP5 Q96HI0 1/20 0.38
SENP2 Q9HC62 1/20 0.38
SENP1 Q9P0U3 1/20 0.38
PPARD Q03181 2/20 0.37
PPARA Q07869 1/20 0.37
PPARG P37231 1/20 0.37
GRN P28799 1/20 0.37
SORT1 Q99523 1/20 0.37
PTPN2 P17706 1/20 0.37
PTPN1 P18031 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25549055 0.90 GPR132 (0.42) CXCR2KIFC1ACEGPR132MRGPRX4
SCHEMBL23460897 0.87 CXCR2 (0.62) CXCR2KIFC1MCHR1MMEACE
SCHEMBL23460899 0.87 CXCR2 (0.62) CXCR2KIFC1MCHR1MMEACE
SCHEMBL23460795 0.87 CXCR2 (0.49) CXCR2KIFC1MCHR1MMEACE
SCHEMBL38147125 0.87 CXCR2 (0.49) CXCR2KIFC1MCHR1MMEACE
SCHEMBL23460794 0.87 CXCR2 (0.49) CXCR2KIFC1MCHR1MMEACE
SCHEMBL38147030 0.86 CXCR2 (0.51) CXCR2KIFC1MCHR1MMEACE
SCHEMBL23461798 0.86 CXCR2 (0.51) CXCR2KIFC1MCHR1MMEACE
SCHEMBL23461802 0.86 CXCR2 (0.51) CXCR2KIFC1MCHR1MMEACE
SCHEMBL23461787 0.85 CXCR2 (0.49) CXCR2KIFC1MMEACECPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA CXCR2 1205/4885KIFC1 4789/4885MCHR1 4613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.